Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 288 participants.
Also called NCT06880770
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 288 participants
- Sponsor
- Registry
-
NCT06880770
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Croatia, Czechia, Georgia, Hungary, Israel, Jordan, Latvia, Lithuania, Mexico, Oman, Saudi Arabia, Serbia, Singapore, Slovakia, South Korea, Sweden, United Arab Emirates, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT06880770. Randomized; quadruple masking; primary purpose treatment. Start 2025-04-24 (actual); primary completion 2029-03 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
- Acronym
- SHASTA-5
- Condition
- Severe Hypertriglyceridemia
- Intervention (Drug)
- Plozasiran
- Intervention (Drug)
- Placebo
- Lead sponsor
- Arrowhead Pharmaceuticals
Record details
- Record id
cardio:ct-nct06880770- Content hash
47b56fd2858c0382865dd2260558a073d135cd46a4d2ae35e2540c7115071c13